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HEPATITIS
An assessment of hepatitis E virus (HEV) in US blood donors and
recipients: no detectable HEV RNA in 1939 donors tested and no
evidence for HEV transmission to 362 prospectively
followed recipients
Chenyu Xu, Richard Y. Wang, Cathy A. Schechterly, Shengxiang Ge, James W. Shih, Ning-Shao Xia,
Naomi L.C. Luban, and Harvey J. Alter
BACKGROUND: Hepatitis E virus (HEV) infection has
become relevant to blood transfusion practice because
isolated cases of blood transmission have been
reported and because HEV has been found to cause
chronic infection and severe liver disease in immunocompromised patients.
STUDY DESIGN AND METHODS: We tested for
immunoglobulin (Ig)G and IgM antibodies to the HEV
and for HEV RNA in 1939 unselected volunteer US
blood donors. Subsequently, we tested the same variables in pre- and serial posttransfusion samples from
362 prospectively followed blood recipients to assess
transfusion risk.
RESULTS: IgG anti-HEV seroprevalence in the total
1939 donations was 18.8%: 916 of these donations
were made in 2006 at which time the seroprevalence
was 21.8% and the remaining 1023 donations were in
2012 when the seroprevalence had decreased to 16.0%
(p < 0.01). A significant (p < 0.001) stepwise increase in
anti-HEV seroprevalence was seen with increasing age.
Eight of 1939 donations (0.4%) tested anti-HEV IgM
positive; no donation was HEV RNA positive. Two
recipients had an apparent anti-HEV seroconversion,
but temporal relationships and linked donor testing
showed that these were not transfusion-transmitted
HEV infections.
CONCLUSION: No transfusion-transmitted HEV infections were observed in 362 prospectively followed blood
recipients despite an anti-HEV seroprevalence among
donations exceeding 16%.

H

epatitis E virus (HEV) infection has been recognized as an important cause of acute, often
epidemic, hepatitis in Asia and was believed
to be rare in industrialized countries.1,2
However, indigenous HEV infections are increasingly
reported in developed nations, and most are caused by
HEV Genotypes 3 or 4 compared to Genotypes 1 and 2 that
are associated with large outbreaks due to contaminated
water supplies.3,4 In addition, HEV seroprevalence among
blood donors and the general population in industrialized
countries has been found to be much higher than
expected and accumulating evidence suggests that the
clinical importance of HEV infection in nonendemic
regions has been underestimated.5-7 The routes of transmission in countries with safe water supplies are not well
defined, although transmission from contaminated pork
ABBREVIATIONS: HEV = hepatitis E virus; LOD = limit of
detection.
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products has been demonstrated in southwestern France
and other regions.5,8-10
The high seroprevalence of infection in asymptomatic individuals raises the potential risk of HEV transmission through blood transfusion. Although such
transmission appears to be rare, a small number of
transfusion-related cases have been reported and confirmed by molecular identity of the agent in donor and
recipient.11-13 Importantly, this infection, once thought
to be universally self-limiting, has now been shown to
result in chronic infection and cirrhosis in immunecompromised patients and to exacerbate fibrosis progression and liver-related mortality in infected subjects with
existing liver disease.13-15 The potential risk of blood transmission is compounded by the high proportion of blood
recipients who are immunosuppressed and repeatedly
transfused.
In the United States, HEV seroprevalence was found
to be 21% in a national health survey (National Health and
Nutrition Survey [NHANES] III) conducted from 1988 to
199416 and then to have fallen to 6.4% in a similar survey
(NHANES IV) conducted by the Centers for Disease
Control from 2009 to 2010.17 The reason for the decrease in
HEV seroprevalence between these two surveys is currently unexplained. To better assess the risk of HEV transmission by blood transfusion we investigated HEV
seroprevalence among healthy US blood donors and
tracked transmission rates among blood recipients
enrolled in an ongoing prospective study of transfusiontransmitted infections (TRIPS). We utilized a commercial
anti-HEV assay that performed well in comparative studies18 and a sensitive in-house polymerase chain reaction
(PCR) assay validated with plasma from persons confirmed to have HEV Genotype 3 infection.

MATERIALS AND METHODS

Medical Center (Washington, DC) and from Suburban
Hospital (Bethesda, MD). Informed consent was obtained
from all donors and recipients in accordance with the
Declaration of Helsinki for participation in NIHsponsored and institutional review board–approved protocols (NIH Protocol 01-CC-0231; Children’s National
Medical Center, Protocol 2540). Human subjects were
assigned a code number, and all TRIPS patient samples
and both linked and unlinked donor samples were identified only by that code; the testing laboratories had no
capability of linking the code number to the study participant’s name.

Anti-HEV serology
Anti-HEV immunoglobulin (Ig)G and IgM antibodies were
detected by enzyme-linked immunosorbent assay using
assays manufactured by Wantai Pharmaceutical Co.,
Beijing, China (research use only). This assay utilizes a
recombinant peptide corresponding to open reading
frame 2 (ORF2) of the HEV genome.19 According to the
package insert, this assay has a specificity of 98.6% in
testing 9012 healthy Asian subjects. It is to be noted that
confirmatory assays for HEV IgM and IgG antibodies are
not available rendering positive findings only presumptive. Testing was performed according to the manufacturer’s instructions. Briefly, samples were diluted 1:10, added
to antigen-coated plates and incubated for 30 minutes.
Horseradish peroxidase conjugate was then added and
followed by an additional 30 minutes of incubation. After
incubation, color development was measured at an absorbance of 450 nm. Results were calculated as sample-tocutoff ratios: values of 1.0 or above were considered
reactive. Each sample was tested in duplicate and all positive samples were confirmed in a repeat duplicate assay.
Only samples reactive in at least three of the four quadruplicate assays were considered positive.

HEV specimens
In our study, all tests were performed on plasma samples.
In the donor study, we used unselected National Institutes
of Health (NIH) volunteer blood donor samples obtained
in two different time periods, specifically 2006 and 2012.
In the recipient study, samples were tested before transfusion and then at 4 and/or 8 weeks posttransfusion, and at
the end of the study (24 or 36 weeks posttransfusion): 21%
of recipients had a presample and three posttransfusion
samples and all recipients had a presample and at least
one sample obtained 8 or more weeks after transfusion.
Linked donor samples were available for most recipients.
Donor samples used for determination of HEV seroprevalence were not linked to specific recipients.
The TRIPS repository was initiated in November 2001
and is composed of linked donor–recipient specimens
from transfusion recipients enrolled at the NIH Clinical
Center (Bethesda, MD) and the Children’s National
2506
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HEV RNA detection
Pools of seven to eight donor samples were tested for HEV
RNA by both real-time reverse transcription–PCR20 and a
nested PCR.21 The 95% limit of detection (LOD) for the
real-time PCR assay was 400 IU/mL and the 50% LOD was
200 IU/mL. For the nested PCR, the 95% LOD was
200 IU/mL and the 50% LOD was 50 IU/mL. IgM-positive
samples were tested individually by both PCR methods.
Nucleic acid isolation was performed using a viral RNA
mini kit (QIAamp, Qiagen, Chatsworth, CA) according to
the manufacturer’s instructions. For real-time PCR, highly
conserved sequences in the ORF3 region of all HEV
genotypes were targeted: forward primer (JVHEVF; 5′
-GGTGGTTTCTGGGGTGAC-3′), reverse primer (JVHEVR:
5′-AGGGGTTGGTTGGATGAA-3′), and probe (JVHEVP:
FAM-5′-TGATTCTCAGCCCTTCGC-3′-TAMRA). For nested
PCR, a 150-nucleotide segment of ORF2 was amplified

HEV IN US BLOOD DONORS AND RECIPIENTS

TABLE 1. Hepatitis E markers in NIH volunteer blood donors*
Collection year
2006
2012
Total

Number tested
916
1023
1939

Anti-HEV IgG positive
200 (21.8), 19.2% to 24.5%
164 (16.0), 13.8% to 18.3%
364 (18.8), 17.0% to 20.5%

Anti-HEV IgM positive
3 (0.3), -0.0% to 0.7%
5 (0.5), -0.0% to 0.9%
8 (0.4), 0.1% to 0.7%

HEV RNA positive
0 (0)
0 (0)
0 (0)

* Data are reported as number (%), 95% CI.

with primers E1 (5′- CTGTTTAAYCTTGCTGACAC-3′) and
E5 (5′-WGARAGCCAAAGCACATC-3′) in the first round of
PCR and primers E2 (5′-GACAGAATTGATTTCGTCG-3′)
and E4 (5′-TGYTGGTTRTCRTAATCCTG-3′) in the second
round. PCR cycling conditions for both rounds consisted
of 35 cycles of denaturation at 94°C for 30 seconds,
annealing at 53°C for 30 seconds, and extension at 72°C
for 40 seconds. A positive HEV RNA control (200 IU/mL)
was included in each assay.

Statistical analysis
All statistical analysis was performed with computer software (IBM SPSS Statistics 19, IBM Corp., Armonk, NY)
where p values of less than 0.05 were consider as
significant.

Fig. 1. Distribution of sample-to-cut off ratios for HEV IgG in
positive and negative samples from 1939 NIH volunteer blood
donors.

RESULTS
Donor testing
General characteristics of the 1939 blood donations examined are summarized in Table 1. The first 916 samples
were collected from January 3, 2006, to May 19, 2006. The
remaining 1023 donations were collected from January 3,
2012, to March 21, 2012. HEV IgG was detected in 364
(18.8%) of the total 1939 blood donations (95% confidence
interval [CI], 17.0%-20.5%). The ranges of sample-tocutoff ratios for positive and negative samples showed
a clear bimodal distribution (Fig. 1). The mean ⫾ SD
sample-to-cutoff ratio of the positive samples was
8.15 ⫾ 5.06. The seroprevalence was 21.8% (95% CI,
19.2%-24.5%) in year 2006 samples and 16.0% (95% CI,
13.8%-18.3%) in year 2012 samples (p < 0.01).
We analyzed three demographic variables for their
association with IgG seroprevalence using the samples
obtained in 2006. No significant association was found in
regard to sex or race (data not shown). There was a strong
statistical association with age (p < 0.001): the seroprevalence of anti-HEV IgG was 3.4% (95% CI, 0.7%-6.0%) in
ages below 25 and then increased linearly to 42.2% (95%
CI, 31.8%-52.6%) in those over age 65 (Fig. 2). Age data
were not available for samples obtained in 2012. There
were eight donations that tested anti-HEV IgM reactive
among the 1939 donations (0.4%). HEV RNA was not
detected in any donations.

Fig. 2. Prevalence of anti-HEV IgG in 916 NIH volunteer blood
donors by age group.

Recipient testing
The anti-HEV IgG seroprevalence of the 362 recipients in
their pretransfusion samples was 21.5% (95% CI, 17.3%25.8%) and thus very similar to the blood donor population. One recipient (0.3%) was IgM anti-HEV positive in
the pretransfusion sample, but no recipient was IgM antiHEV positive in any posttransfusion sample.
Volume 53, October 2013 TRANSFUSION
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was only 4 days, we conclude that IgG
antibody detected in the patient was
passively transferred from the donated
unit with high-titer anti-HEV and hence
did not indicate a true seroconversion
or a transfusion-associated HEV infection. Unfortunately, the patient died
soon after receipt of the HEV RNA–
positive blood donation so that we
could not trace whether that blood
unit would have transmitted HEV
infection.
In the potential anti-HEV seroconversion Recipient 2, all posttransfusion
samples showed low-level anti-HEV
reactivity with sample-to-cutoff ratios
gradually increasing from 1.5 at Week 4
to 2.5 at Week 24 posttransfusion
(Fig. 3). Neither IgM anti-HEV nor HEV
RNA was detected in any posttransfusion sample. Although the pretransfusion sample was below the assay cutoff
Fig. 3. Suspected, but unconfirmed anti-HEV IgG seroconversion in two blood recipiand thus interpreted as negative, in retents. Recipient 1 received one HEV RNA–positive and one high-titer anti-HEV IgG–
rospect it was just below the cutoff and
positive blood unit 4 days before the sample collected at 36 weeks after the index
probably the onset of an anti-HEV
study transfusion. The patient died shortly after receiving the HEV RNA–positive unit
response that preceded study enrolland thus the consequences of that transfusion could not be assessed. Recipient 2
ment. The cause of this anti-HEV
could be interpreted as having a very early seroconversion posttransfusion, but
response is unknown, but we conclude
more likely was infected before the index transfusion based on the timing and on the
that it was not related to the index transpretransfusion sample having a relatively high, albeit below cutoff.
fusion in this study. None of the linked
donations tested in this case had HEV
markers, but we only had access to two of five donations to
Among the 362 recipients there were two instances
this patient.
(0.6%) where the last posttransfusion sample was antiThese two cases illustrate the importance of having
HEV positive while the pretransfusion sample was antiserial recipient samples and linked donations in interpretHEV negative. These potential anti-HEV seroconversions
ing apparent recipient seroconversion after blood transwere further investigated. In Recipient 1, we tested all
fusion. In sum, we did not observe any cases of
available samples from the time of transfusion to the end
transfusion-transmitted HEV infection among 362 proof study sample that tested anti-HEV positive. Each of
spectively followed blood recipients despite the high serothese interim samples, obtained at 4, 12, and 20 weeks
prevalence of anti-HEV IgG in our population. The
posttransfusion, tested negative for anti-HEV IgM and IgG
observation of zero HEV infections among 362 recipients
and for HEV RNA (Fig. 3). Thus, the finding of anti-HEV in
could represent a true infection rate up to 0.8% based on
the late posttransfusion sample was an isolated, albeit
the upper bound of the 95% CI according to the “rule of
reproducible finding. Next we tested linked donations:
3.”22,23
such samples were available for 69 of the 72 blood products received by this patient during the course of the
DISCUSSION
study. In the 69 linked donations tested, the anti-HEV IgG
seroprevalence was 14.5% (95% CI, 6.0%-23.0%). One of
The results of our study show an anti-HEV IgG seroprevathe IgG-positive donations was also anti-HEV IgM reaclence approaching 19% in testing 1939 blood donations.
tive. Four days before the recipient sample that tested
This proportion is similar to previous studies16 and conanti-HEV IgG positive, this repeatedly transfused patient
firms that exposure to HEV is common in the US blood
received blood from a donation that was HEV RNA posidonor population. Although the seroprevalence appears
tive by nested PCR and from a second donation that had
to have decreased over the 6-year interval between 2006
high-titer anti-HEV (sample-to-cutoff ratio > 20). Since
and 2012, evidence of recent or past HEV exposure
the interval from transfusion of these HEV-reactive blood
remains very high. In general population surveys condonations to the detection of anti-HEV in the recipient
ducted by Centers for Disease Control and Prevention
2508
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(NHANES), a more striking decline in anti-HEV seroprevalence was observed between 1988 to 1994 and 2009 to
2010 with a decrease from 21% to 6%.16,17 Continued monitoring of HEV seroprevalence will be important to elucidate the root causes of transmission.
Estimates of HEV seroprevalence are highly dependent on assay sensitivity and more recently employed
assays appear to be both more sensitive and more specific. The anti-HEV assay utilized in this study was manufactured by Wantai Pharmaceutical Co. and is now widely
used in Asia and Europe where its enhanced sensitivity
has resulted in large increases in anti-HEV seroprevalence compared with earlier assays.5,18,24-26 The difference
between the HEV seroprevalence observed in our study
of blood donors in 2012 (16%) compared to the NHANES
IV population survey in 2009 to 2010 (6%) may in part
reflect test sensitivity rather than true differences in seroprevalence in the tested populations. Although preliminary studies indicate that the increased sensitivity of the
Wantai assay does not come at the expense of diminished
specificity, there is great need to develop HEV standards
and pedigreed panels to allow valid comparisons among
the competing assays to determine whether differences
in seroprevalence are geographic or epidemiologic or
simply assay dependent. Such panels are now under
development.
No HEV viremia was detected in the approximate
2000 donations tested in this study, but this number of
donations is too small to detect a low occurrence event
and much larger surveys are needed. We did, however, find
a small percentage of donations with IgM reactivity suggesting recent infection and posing the potential for relevant incident infections in the donor population. Indeed,
although we did not find an HEV RNA–positive donation
in the donor testing phase of this study, we did find an
HEV RNA–positive donation when retrospectively testing
linked donations to a case of potential transfusionassociated anti-HEV seroconversion. These indications of
recent HEV infections in blood donors indicate the need
for continued vigilance for HEV in the blood supply and
the need for recipient tracing through prospective studies
and lookback investigations. In our study, as in others,5,16
advancing age is a key correlate of anti-HEV seroprevalence. It is probable that this represents cumulative exposure over time, but an alternate explanation is that there is
a cohort effect wherein the population had an unidentified, nonlethal HEV exposure in the remote past and the
resulting antibody response has been carried forward into
old age.
Sporadic cases of transfusion-related HEV infection
have been reported recently11-13 and have been confirmed
by molecular linkage between donor and recipient. Thus,
the issue at hand is not whether HEV can be transmitted
by transfusion, but rather how often and with what
consequences?

In the prospective arm of our study, we tested preand posttransfusion samples from 362 recipients. The
HEV seroprevalence of the recipients before transfusion
was very similar to that of the blood donors we tested
suggesting that HEV exposure and infection is widespread
in the US population. Most recipients in our study
received blood from at least five donations enhancing the
possibility that a patient would receive blood from a donor
previously infected with HEV. Based on the average transfusion number and the 0.4% seroprevalence of IgM antiHEV, recipients in this study would have had a 1% to 2%
chance of receiving blood from a recently infected, IgMpositive blood donor.
Two recipients (0.6%) among the 362 total recipients
prospectively followed had an apparent anti-HEV IgG
seroconversion suggesting transfusion-transmitted HEV
infection. However, in one of these recipients, IgG antiHEV was detected in only the last study sample at 36
weeks after his first within-study transfusion. No IgM antibody or HEV RNA was detected in posttransfusion
samples obtained before the appearance of IgG anti-HEV.
Investigation of linked donations to this repeatedly transfused recipient revealed that the patient was transfused
with a strongly reactive anti-HEV–positive donation just
before the detection of anti-HEV in his last follow-up
sample. Thus, the antibody detected in this recipient was
passively transferred and not indicative of HEV infection
followed by anti-HEV seroconversion. Interestingly, the
patient also received an HEV RNA–positive and an IgM
anti-HEV–positive blood unit 4 days before our last study
sample. The patient died soon thereafter and thus we
could not trace the outcome of HEV-positive blood donations. However, this does demonstrate that HEV RNA–
positive donors exist in our donor population even though
none were detected in the approximate 2000 donations
tested in the donor serosurvey.
In the second recipient demonstrating suspected
seroconversion, retrospective testing revealed that all his
posttransfusion samples were weakly reactive for antiHEV beginning with the 4-weeks-posttransfusion sample
(Fig. 3). No sample was IgM anti-HEV or HEV RNA positive. Linked donations did not reveal an HEV-infected
donor, but some donations were not available for testing.
Further examination of this patient’s pretransfusion
sample showed that although it fell below the cutoff of the
assay and hence was interpreted as anti-HEV negative, in
fact, the OD reading was just below the cutoff and might
have represented the onset of anti-HEV seroconversion,
which then increased incrementally throughout followup. This scenario is compatible with an HEV exposure that
occurred before the index transfusion in this study. We
conclude from these two cases that neither patient was
HEV infected as the result of blood transfusion administered within the time frame of the study. More importantly, we conclude that in the proper interpretation of
Volume 53, October 2013 TRANSFUSION
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apparent antibody seroconversions, it is vital to examine
serial recipient samples and to have linked donor samples.
Access to such samples is only possible in a prospective
study design.
Overall, this study concludes that past exposure to
HEV is common in the US donor population, that a small
proportion of such donors have IgM antibody suggestive
of recent exposure, and that a very small proportion
harbor HEV RNA. Thus, the potential for transfusiontransmitted HEV infection clearly exists and indeed has
been confirmed in several case reports.11-13 Therefore, the
issue at hand is not whether HEV can be transmitted by
transfusion, but rather whether the frequency of such
transmission and the clinical consequences of the infection warrant donor screening for this agent? HEV fulfills
the essential criteria for an agent that might justify blood
donor screening in that it can be found in asymptomatic
individuals, it has been proven to be transmitted by transfusion and it can cause significant disease in immunocompromised patients who now constitute a large
segment of hospitalized blood recipients. What we do not
know is the magnitude of the problem and the likelihood
that an asymptomatic HEV carrier would present to a
donor center and be otherwise eligible to donate.
Although prolonged asymptomatic viremia has been
observed in immunocompromised individuals, it has not
been documented in healthy blood donors. We know from
studies of other blood-transmitted agents that it is the
duration of asymptomatic viremia that best defines the
transfusion risk. Agents such as hepatitis A virus that have
an extremely brief duration of asymptomatic viremia pose
little risk whereas hepatitis B virus and hepatitis C virus,
which have prolonged periods of asymptomatic viremia,
pose major threats and necessitate donor screening by
both serology and nucleic acid testing.
Although we did not detect any transfusionassociated HEV infections among 362 prospectively followed recipients in our study, calculation of the upward
bound for zero observations indicates that HEV transmission could have occurred in up to 0.8% of recipients.
Further, the finding of IgM anti-HEV in the absence of
HEV RNA in 0.4% of donors allows for the possibility that
these donors could have been infectious had they donated
days to weeks earlier when they might have been HEV
RNA positive. In addition, although we did not find an
HEV RNA–positive donor in a serosurvey of 1939 donors,
we did detect one HEV RNA–positive donor during investigation of an apparent anti-HEV seroconversion in a
recipient. Thus, it is probable that HEV-positive US blood
donors will be detected when much larger serosurveys are
performed. The most immediate need for the study of
HEV and blood transfusion is to test tens of thousands of
donors for HEV RNA and then to follow those found positive to determine the duration of viremia. If few RNApositive donors are identified, as in our study, and if the
2510
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duration of viremia in immune-competent individuals is
very short, then routine donor screening will not be necessary. In contrast, if the occurrence of viremia is frequent
and the duration of viremia prolonged, then donor
screening would be indicated since the disease consequences in those recipients who are immune-suppressed
and in those with existing liver diseases can be dire.
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